CAPPED BONUS CERTIFICATE - GALAPAGOS | Market Closed - Euronext Paris 02:17:34 2024-05-15 EDT | ||
| 46.63 EUR | +0.60% |
|
| Current month | +4.89% | ||
| 1 month | +2.73% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GALAPAGOS NV
Latest news about GALAPAGOS NV
| Date | Price | Change |
|---|---|---|
| 24-05-15 | 46.63 | +0.60% |
| 24-05-14 | 46.35 | -0.69% |
| 24-05-13 | 46.67 | +1.79% |
| 24-05-10 | 45.85 | -0.22% |
| 24-05-09 | 45.95 | +0.04% |
Real-time Euronext Paris
Last update May 15, 2024 at 02:17 am
More quotesStatic data
| Product type | Certificati Bonus e Protezione parz. |
|---|---|
| Buy / Sell | CALL |
| Underlying | GALAPAGOS NV |
| Issuer | 
Société Générale
|
| SR21S | |
| ISIN | NLSGE001BFC0 |
| Date issued | 2022-12-20 |
| Strike | 47.7 € |
| Maturity | 2024-06-21 (38 Days) |
| Parity | 1 : 1 |
| Emission price | 38.05 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 46.76 € |
|---|---|
| Lowest since issue | 36.99 € |
| Spread | 0.55 € |
| Spread % | 1.18% |
Company Profile
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. The company is committed to improving patients' lives worldwide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.
Sector
-
Consensus: Galapagos NV
Sell
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
26.42
EUR
Average target price
37.03
EUR
Spread / Average Target
+40.16%
- Stock Market
- Certificates
- SR21S Certificat